https://scholars.lib.ntu.edu.tw/handle/123456789/517579
標題: | Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections | 作者: | Kamm?ller M. TSEN-FANG TSAI Griffiths C.E.M. Kapoor N. Kolattukudy P.E. Brees D. Chibout S.-D. Safi J. Jr. Fox T. |
公開日期: | 2017 | 出版社: | Nature Publishing Group | 卷: | 6 | 期: | 8 | 起(迄)頁: | e152 | 來源出版物: | Clinical and Translational Immunology | 摘要: | Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and in vitro findings examining the effect of secukinumab on Mycobacterium tuberculosis infection. We re-assessed the effect of secukinumab on the incidence of acute tuberculosis (TB) and reactivation of latent TB infection (LTBI) in pooled safety data from five randomized, double-blind, placebo-controlled, phase 3 clinical trials in subjects with moderate to severe plaque psoriasis. No cases of TB were observed after 1 year. Importantly, in subjects with a history of pulmonary TB (but negative for interferon-γ release and receiving no anti-TB medication) or positive for latent TB (screened by interferon-γ release assay and receiving anti-TB medication), no cases of active TB were reported. Moreover, an in vitro study examined the effect of the anti-tumor necrosis factor-α (TNFα) antibody adalimumab and secukinumab on dormant M. tuberculosis H37Rv in a novel human three-dimensional microgranuloma model. Auramine-O, Nile red staining and rifampicin resistance of M. tuberculosis were measured. In vitro, anti-TNFα treatment showed increased staining for Auramine-O, decreased Nile red staining and decreased rifampicin resistance, indicative of mycobacterial reactivation. In contrast, secukinumab treatment was comparable to control indicating a lack of effect on M. tuberculosis dormancy. To date, clinical and preclinical investigations with secukinumab found no evidence of increased M. tuberculosis infections. ? The Author(s) 2017. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033240996&doi=10.1038%2fcti.2017.34&partnerID=40&md5=abba9e4d45c89e2f9fa5f9116aa0b945 https://scholars.lib.ntu.edu.tw/handle/123456789/517579 |
ISSN: | 2050-0068 | DOI: | 10.1038/cti.2017.34 | SDG/關鍵字: | adalimumab; alanine aminotransferase; aspartate aminotransferase; bilirubin; gamma interferon; isoniazid; liver enzyme; rifampicin; secukinumab; alanine aminotransferase blood level; antibiotic resistance; Article; aspartate aminotransferase blood level; bilirubin blood level; chemoprophylaxis; colony forming unit; combination drug therapy; comparative study; controlled study; double blind procedure; drug effect; drug safety; enzyme blood level; human; human cell; hypertransaminasemia; in vitro study; incidence; interferon gamma release assay; latent tuberculosis; lung tuberculosis; major clinical study; medical history; observational study; phase 3 clinical trial (topic); priority journal; Psoriasis Area and Severity Index; psoriasis vulgaris; randomized controlled trial (topic); recurrent infection; retrospective study; side effect; staining |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。